Bevacizumab in the treatment of ovarian cancer

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thus MJ. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.21(17), 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: Clinical Gynecologic Oncology (7th Edition). DiSaia PJ, Creasman WT (Eds). Mosby, Inc. 313–367 (2007).
   Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol.20, 1248–1259 (2002).
   PubMed Web of Science ®Google Scholar
• Bookman MA; on behalf of GCIG. GOG182-ICON5: 5-arm Phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. 2006 ASCO Annual Meeting Proceedings Part I24(Suppl. 18), 5002 (2006).
   Google Scholar
• Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354, 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bookman MA, Young RC, du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol. Oncol.103, 1–6 (2006).
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis. Annu. Rev. Med.57, 1–18 (2006).
   PubMed Web of Science ®Google Scholar
• Hirota, K, Semenza GL Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol.59(1), 15–26 (2006).
   PubMed Web of Science ®Google Scholar
• Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol.16(9), 4604–4613 (1996).
   PubMed Web of Science ®Google Scholar
• Paley PJ, Staskus, KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer80, 98–106 (1997).
   PubMed Web of Science ®Google Scholar
• Shen GH, Ghazizadeh M, Kawanami O et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer83(2), 196–203 (2000).
   PubMed Web of Science ®Google Scholar
• Obemair A, Waisicky R, Kaider A et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett.138, 175–182 (1999).
   PubMed Web of Science ®Google Scholar
• Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol.147(1), 9–19 (1995).
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int. J. Gynecol. Cancer14, 815–823 (2004).
   PubMed Web of Science ®Google Scholar
• Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer101, 1364–1374 (2004).
   PubMed Web of Science ®Google Scholar
• Hefler LA, Zeillinger R, Grimm C et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol. Oncol.103, 512–517 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper BC, Ritchie JM, Broghammer CLW et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res.8, 3193–3197 (2002).
   PubMed Web of Science ®Google Scholar
• Zebrowski BK, Liu W, Ramirez K, Akaqi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol.6(4), 373–378 (1999).
   PubMed Web of Science ®Google Scholar
• Sivarkumar B, Harry L, Paleolog EM. Modulating angiogenesis. JAMA292, 972–977 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Sfakiotaki G, Androulakis N et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter Phase II study. BMC Cancer7, 91 (2007).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. E2100: a randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer. Presented at: 41st Annual ASCO Meeting. Orlando, FL, USA, May 13–17, 2005.
   Google Scholar
• Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial – E4599. J. Clin. Oncol.23(1), S2 (2005).
   Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–34 (2003).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57, 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrera N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res.65(3), 671–680 (2005).
   PubMed Web of Science ®Google Scholar
• Kowanetz M and Napoleone F. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res.12(17), 5018–5022 (2006).
   PubMed Web of Science ®Google Scholar
• Dvorak, HF. Discovery of vascular permeability factor (VPF). Exp. Cell Res.312, 522–526 (2006).
   PubMed Web of Science ®Google Scholar
• Nummum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol.102(3), 425–228 (2006).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol.96, 902–905 (2005).
   PubMed Web of Science ®Google Scholar
• Cohn DE, Valmadre S, Resnick KE et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol.102, 134–139 (2006).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Han E, Josephs-Cowan CA et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol.102, 140–144 (2006).
   PubMed Web of Science ®Google Scholar
• Wright JD, Hagemann, A, Rader, JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. Cancer107, 83–89 (2006).
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol.23(Suppl.), S457 (2005) (Abstract 5009).
   Google Scholar
• Garcia AA, Oza AM, Hirte H et al. Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium trial. J. Clin. Oncol.23(Suppl.), S455 (2005) (Abstract 5000).
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis, U, Penson R. et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J. Clin. Oncol. Suppl.24(Suppl. 18), (2006) (Abstract 5006).
   Google Scholar
• Aghajanian C. The role of bevacizumab in ovarian cancer – an evolving story. Gynecol. Oncol.102, 131–133 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology69(Suppl. 3), 25–33 (2005).
   PubMed Web of Science ®Google Scholar
• Friberg, G, Oza AM, Morgan RJ et al. Bevacizumab plus erlotinib for patients with recurrent ovarian and fallopian tube cancer: preliminary results of a multi-center Phase II trial. J. Clin Oncol.24(Suppl. 18) (2006) (Abstract 5018).
   Google Scholar
• Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol. Oncol.105(1), 3–6 (2007).
   PubMed Web of Science ®Google Scholar
• Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer6, 626–635 (2006).
   PubMed Web of Science ®Google Scholar
• Wright JD, Alvarezsecord A, Numnum TM et al. A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. J. Clin Oncol.24(Suppl. 18) (2006) (Abstract 5019).
   Google Scholar
• Bidus MA, Webb JC, Seidman JD et al. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol. Oncol.102, 5–7 (2006).
   PubMed Web of Science ®Google Scholar
• Penson RT, Cannistra SA, Seiden MV et al. Phase II study of carboplatin, paclitaxel, and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. J. Clin. Oncol.24(Suppl. 18) (2006) (Abstract 5020).
   Google Scholar